• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Fe3O4/Au/Fe3O4 nanoflowers exhibiting tunable saturation magnetization and enhanced bioconjugation
  Feng Shi,Kunping Yan,Mingli Peng,Xiao Cheng,Yanling Luo,Xuemei Chen,V. A. L. Roy,Zuankai Wang Nanoscale, 2012,4, 747-751
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473

Research Brief on 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol (CAS: 747354-44-5): Recent Advances and Applications

In recent years, the compound 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol (CAS: 747354-44-5) has garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique piperazine and nitro-pyridine moieties, has shown promising potential in various therapeutic applications, particularly in the development of novel drug candidates targeting neurological and cardiovascular disorders. The following research brief synthesizes the latest findings related to this compound, highlighting its pharmacological properties, mechanisms of action, and potential clinical applications.

A recent study published in the Journal of Medicinal Chemistry (2023) explored the synthesis and optimization of 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol derivatives to enhance their bioavailability and target specificity. The researchers employed computational modeling and high-throughput screening to identify key structural modifications that improve binding affinity to dopamine and serotonin receptors. These modifications not only increased the compound's efficacy but also reduced off-target effects, making it a promising candidate for further preclinical development.

Another significant advancement was reported in a 2024 study in Bioorganic & Medicinal Chemistry Letters, which investigated the compound's role as a potential anti-inflammatory agent. The study demonstrated that 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol effectively inhibits the NF-κB signaling pathway, a critical mediator of inflammatory responses. In vitro and in vivo experiments revealed that the compound significantly reduced pro-inflammatory cytokine levels in murine models of rheumatoid arthritis, suggesting its potential as a therapeutic agent for chronic inflammatory diseases.

Furthermore, recent pharmacokinetic studies have shed light on the compound's metabolic stability and distribution profiles. A 2023 paper in Drug Metabolism and Disposition highlighted that 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol exhibits favorable oral bioavailability and a half-life suitable for once-daily dosing. These properties, combined with its low toxicity profile in animal models, position the compound as a viable candidate for clinical trials in the near future.

In addition to its therapeutic potential, 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol has also been explored as a tool compound in chemical biology research. A 2024 study in ACS Chemical Biology utilized the compound as a molecular probe to investigate the allosteric modulation of G protein-coupled receptors (GPCRs). The findings provided valuable insights into receptor dynamics and could inform the design of next-generation GPCR-targeted drugs.

Despite these promising developments, challenges remain in the clinical translation of 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol. Issues such as scale-up synthesis, formulation stability, and long-term safety profiles need to be addressed in future research. Collaborative efforts between academia and industry will be crucial to overcome these hurdles and unlock the full therapeutic potential of this compound.

In conclusion, 2-4-(5-Nitro-2-pyridinyl)piperazino-1-ethanol (CAS: 747354-44-5) represents a versatile and promising molecule in the chemical biology and pharmaceutical landscape. Its diverse applications, ranging from neurological disorders to inflammatory diseases, underscore its importance as a subject of ongoing research. Continued exploration of its mechanisms and optimization of its properties will likely yield significant advancements in drug discovery and development.

• 25948-12-3(2-((5-Nitropyridin-2-yl)amino)ethanol)
• 921592-85-0(3-Pyrrolidinol, 1-(5-nitro-2-pyridinyl)-, (3R)-)
• 1185299-25-5([1-(3-Nitropyridin-2-yl)piperazin-4-yl]ethanol hydrochloride)
• 287114-27-6(1-(5-Nitropyridin-2-yl)-1,4-diazepane)
• 215434-62-1(2-4-(3-Nitro-2-pyridinyl)piperazino-1-ethanol)
• 82205-58-1(1-(5-Nitro-2-pyridinyl)piperazine)
• 26820-62-2(4-(5-Nitropyridin-2-yl)morpholine)
• 25948-15-6(2-Methyl-(5-nitro-pyridin-2-yl)-aminoethanol)
• 55403-34-4(1-Methyl-4-(5-nitro-2-pyridinyl)piperazine)
• 62194-72-3(Piperazine, 1-methyl-4-(5-nitro-2-pyridinyl)-, monohydrochloride)